With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?  

For women who are eligible for both, we discuss both, but I am biased towards ribociclib for certain. The QOL issues we have had with abemaciclib in the adjuvant setting have been outrageous. Despite best supportive care and dose adjustments, I have women severely limiting their daily activities ar...

I think either is ok. Things to consider: Comorbidities. For example, I would avoid Abemaciclib in patients with active IBD and would avoid Ribociclib in patients with significant heart disease (especially if pre-existing prolonged QTc). Abemaciclib is given at full dose (150 mg bid) for 2 years...

This is an important question. Since we have no direct comparison studies, I do not have a specific recommendation that is evidence-based. Thus, for patients who would have met the eligibility criteria for either study, I am discussing both options. I then discuss duration, medication schedule, lab ...

I question the routine use of either medicine in the adjuvant setting. MonarchE and NATALEE trials each have significant limitations raising concerns over how to interpret the data. Both agents have significant toxicity profiles with unprecedented financial toxicity, and no OS benefit yet seen.I wou...